.png){kind=icon}
.png){kind=icon}
Return
Bladder Cancer. Version 3.2020
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2020.0011.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscleinvasive bladder cancer in the event of a bacillus Calmette-Guerin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org . Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.
Keywords:
BACILLUS-CALMETTE-GUERIN
METASTATIC UROTHELIAL CARCINOMA
TRANSITIONAL-CELL CARCINOMA
PHASE-II TRIAL
BAND IMAGING CYSTOSCOPY
WHITE-LIGHT CYSTOSCOPY
T1 PAPILLARY CARCINOMA
HIGH-RISK TA
HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY
REPEAT TRANSURETHRAL RESECTION
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations